## Abstract CB 1954, a monofunctional alkylating agent, has exceptional activity against the Walker carcinoma yet is inactive against a large number of other animal tumours. A line of the Walker tumour with acquired resistance to CB 1954 was cross‐resistant to Melphalan, implying a common mechanism
Studies on the reversal of the selective antitumour effect of the aziridinyl derivative cb 1954 by 4-amino-5-imidazolecarboxamide
✍ Scribed by T. A. Connors; H. G. Mandel; D. H. Melzack
- Publisher
- John Wiley and Sons
- Year
- 1972
- Tongue
- French
- Weight
- 435 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The selective toxicity of CB 1954 (5‐aziridinyl‐2,4‐dinitrobenzamide) for Walker tumour cells, previously shown in the whole animal and in an in vitro/in vivo system, has been confirmed in an in vitro system In each case its actions on the Walker tumour were reversed by 4‐amino‐5‐imidazolecarboxamide, the ribotide of which is a purine precursor, provided it was given before or soon after the CB 1954. Other purines also produced this reversal, while pyrimidines and several other compounds did not. This evidence suggested that CB 1954, in addition to its alkylating properties, had features of a purine antimetabolite. However, anthranilamide was also very effective in protecting against CB 1954, suggesting that reversal could be achieved by compounds structurally related to CB 1954 which competed with it for some receptor site.
📜 SIMILAR VOLUMES
Division of Biochemical Development and Molecular Diwaies, The Childrcn'i Hospital of f h r / d d t ~/ p h i a , and Departments of fudiatrics arid Medicine, University of fenn~y/vdnia School of Mcdicine, fhiladelphrd, Pcvmsylvania 7 9 7 04 The present investigation evaluates the effect of AICA-Ribo